A review of NTRK fusions in cancer

Manea, Cristina Alexandra; Badiu, Dumitru Cristinel; Ploscaru, Ioan Cristian; Zgură, Anca; Bacinschi, Xenia; Smarandache, Cătălin Gabriel; Serban, Dragos; Popescu, Cristian Gabriel; Grigorean, Valentin Titus; Botnarciuc, Vladimir

doi:10.1016/j.amsu.2022.103893

Cited by 40 publications

(20 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 The prevalence of fusion events involving NTRK genes in solid tumors is as high as 1% and has been discovered in at least 34 types of cancer. 6 Drugs targeting central genes have been proven effective against cancer driven by their fusion genes. As an example, TRK inhibitors such as entrectinib and larotrectinib have been shown to be effective in various NTRK-fusion-positive solid tumor diseases.…”

Section: Discussionmentioning

confidence: 99%

“…(NTRK) gene fusions have been reported in at least 34 cancer types and are considered biomarkers for predicting drug resistance and survival. 6 The small-molecule inhibitor larotrectinib 7 provides a targeted treatment option for NTRK gene fusions present in various cancer types. Targeted therapy drugs for fusion genes have been approved and widely used in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anchored-fusion enables targeted fusion search in bulk and single-cell RNA sequencing data

Yuan,

Wang,

Sun

et al. 2024

Cell Reports Methods

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anchored-fusion enables targeted fusion search in bulk and single-cell RNA sequencing data

Yuan,

Wang,

Sun

et al. 2024

Cell Reports Methods

View full text Add to dashboard Cite

“…NTRK gene fusion is a carcinogenic driver for various tumor types [ 38 ]. NTRK gene fusion is very common in some rare tumors, but also occurs in solid tumors, but the probability is very small, which includes thyroid cancer [ 39 ]. In response to such genetic abnormalities, new targeted drugs have been designed to treat related malignant tumors.…”

Section: Discussionmentioning

confidence: 99%

Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials

Wang,

Zhang,

Xing

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background Thyroid cancer is a leading endocrine malignancy, with anaplastic and medullary subtypes posing treatment challenges. Existing therapies have limited efficacy, highlighting a need for innovative approaches. Methods We analyzed 658 articles and 87 eligible clinical trials using bibliometric tools and database searches, including annual publication and citation trends, were executed using Web of Science, CiteSpace, and VOS Viewer. Results Post-2018, there is a surge in thyroid cancer immunotherapy research, primarily from China and the University of Pisa. Of the 87 trials, 32 were Phase I and 55 were Phase II, mostly exploring combination therapies involving immune checkpoint inhibitors. Conclusion The study's dual approach verifies the swift advancement of thyroid cancer immunotherapy from diverse perspectives. Immune checkpoint inhibitors have become the preferred regimen for advanced MTC and ATC in late therapeutic lines. However, since ICB plays a pivotal role in ATC, current clinical trial data show that ATC patients account for more and the curative effect is more accurate. Anticipated future developments are inclined toward combination regimens integrating immunotherapy with chemotherapy or targeted therapies. Emerging approaches, such as bispecific antibodies, cytokine-based therapies, and adoptive cell therapies like CAR-T and TCR-T, are exhibiting considerable potential. Upcoming research is expected to concentrate on refining the tumor immune milieu and discovering novel biomarkers germane to immunotherapeutic interventions.

show abstract

“…The family of neurotrophic tropomyosin kinase receptors (NTRK) is a transmembrane tyrosine kinase that is integral to neural development through the activation of growth signaling pathways. NTRK protein fusions have been implicated in multiple solid tumor malignancies [ 46 ]. NTRK inhibitors Intrectinib and Larotrectinib are accepted as targeted treatment options for patients with metastatic biliary tract cancers harboring NTRK fusion genes, which make up <1% of these cancers.…”

Section: Molecular Targetsmentioning

confidence: 99%

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review

Hadfield,

DeCarli,

Bash

et al. 2023

IJMS

View full text Add to dashboard Cite

Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody–drug conjugates. This review provides an overview of the current landscape of treatment options, as well as promising future therapeutic targets.

show abstract

A review of NTRK fusions in cancer

Cited by 40 publications

References 54 publications

Anchored-fusion enables targeted fusion search in bulk and single-cell RNA sequencing data

Anchored-fusion enables targeted fusion search in bulk and single-cell RNA sequencing data

Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review

Contact Info

Product

Resources

About